FY2022 EPS Estimates for Neurocrine Biosciences, Inc. Lowered by Oppenheimer (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. (NASDAQ:NBIXGet Rating) – Equities researchers at Oppenheimer reduced their FY2022 earnings per share (EPS) estimates for Neurocrine Biosciences in a note issued to investors on Wednesday, May 4th. Oppenheimer analyst J. Olson now forecasts that the company will post earnings of $1.81 per share for the year, down from their previous estimate of $2.27. Oppenheimer also issued estimates for Neurocrine Biosciences’ FY2023 earnings at $5.05 EPS and FY2025 earnings at $9.13 EPS.

Several other equities research analysts have also recently issued reports on the stock. Zacks Investment Research raised shares of Neurocrine Biosciences from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 21st. Mizuho dropped their target price on shares of Neurocrine Biosciences from $103.00 to $95.00 in a research report on Monday, February 14th. Jefferies Financial Group downgraded shares of Neurocrine Biosciences to a “hold” rating and set a $94.00 price objective for the company. in a research note on Thursday, March 3rd. Barclays boosted their price objective on Neurocrine Biosciences from $100.00 to $110.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $140.00 price target on shares of Neurocrine Biosciences in a research note on Monday, February 14th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $112.13.

NBIX opened at $79.55 on Monday. Neurocrine Biosciences has a 12 month low of $71.88 and a 12 month high of $108.01. The business has a 50-day moving average of $93.13 and a two-hundred day moving average of $87.90. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.02 and a quick ratio of 3.83. The stock has a market capitalization of $7.60 billion, a price-to-earnings ratio of 110.49 and a beta of 0.70.

Neurocrine Biosciences (NASDAQ:NBIXGet Rating) last announced its quarterly earnings data on Wednesday, May 4th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.21). Neurocrine Biosciences had a net margin of 5.91% and a return on equity of 5.30%. The business had revenue of $310.60 million during the quarter, compared to analysts’ expectations of $304.07 million. During the same period in the prior year, the firm earned $0.33 EPS. Neurocrine Biosciences’s revenue for the quarter was up 31.3% on a year-over-year basis.

A number of hedge funds have recently made changes to their positions in NBIX. Whittier Trust Co. boosted its holdings in shares of Neurocrine Biosciences by 102.8% in the fourth quarter. Whittier Trust Co. now owns 290 shares of the company’s stock valued at $25,000 after buying an additional 147 shares during the period. IndexIQ Advisors LLC acquired a new position in shares of Neurocrine Biosciences during the first quarter worth about $27,000. Moors & Cabot Inc. bought a new position in shares of Neurocrine Biosciences during the third quarter worth about $30,000. KB Financial Partners LLC acquired a new stake in Neurocrine Biosciences in the 4th quarter valued at approximately $33,000. Finally, Orion Capital Management LLC bought a new stake in Neurocrine Biosciences in the 4th quarter valued at approximately $34,000. Hedge funds and other institutional investors own 93.21% of the company’s stock.

In related news, Director Gary A. Lyons sold 15,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, April 25th. The shares were sold at an average price of $92.76, for a total transaction of $1,391,400.00. Following the transaction, the director now owns 208,697 shares of the company’s stock, valued at approximately $19,358,733.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Darin Lippoldt sold 300 shares of the company’s stock in a transaction that occurred on Friday, March 18th. The shares were sold at an average price of $95.00, for a total transaction of $28,500.00. The disclosure for this sale can be found here. Insiders sold a total of 34,483 shares of company stock valued at $3,241,957 in the last quarter. Corporate insiders own 4.40% of the company’s stock.

About Neurocrine Biosciences (Get Rating)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.

Featured Stories

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.